FCE 28260
Appearance
(Redirected from FCE-28260)
![]() | |
Clinical data | |
---|---|
Other names | PNU 156765 |
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C28H35F3N2O2 |
Molar mass | 488.595 g·mol−1 |
3D model (JSmol) | |
| |
|
FCE 28260 is an azasteroidal 5α-reductase inhibitor which was developed for the treatment of benign prostatic hyperplasia and androgenic alopecia (pattern hair loss) in the 1990s but was never marketed.[1][2][3] FCE 28260 has been found to inhibit rat and human 5α-reductase with half-maximal inhibitory concentrations (IC50) of 15 and 16 nM, respectively, while finasteride had values of 30 and 52 nM.[1]
References
[edit]- ^ a b Giudici D, Briatico G, Cominato C, Zaccheo T, Iehlè C, Nesi M, et al. (June 1996). "FCE 28260, a new 5 alpha-reductase inhibitor: in vitro and in vivo effects". The Journal of Steroid Biochemistry and Molecular Biology. 58 (3): 299–305. doi:10.1016/0960-0760(96)00040-4. PMID 8836165. S2CID 140209512.
- ^ EP 0782582, di Salle E, Nesi M, Panzeri A, "Epimers of (22RS)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide", published 1997-07-09
- ^ "FCE 28260". AdisInsight. Springer Nature Switzerland AG.